Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 1988 - 1991
  • Resident, Medicine, University of Texas at Dallas 1985 - 1988
  • M.D., University of Texas at Dallas 1985
• 

  Duke Appointment History

  • Professor of Medicine, Medicine, Hematological Malignancies, Medicine 2012 - 2017
  • Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2012
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2010
  • Associate Clinical Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2006
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1994 - 2004
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1991 - 1994
• Research
• 

  Selected Grants

  • EQAPOL - Years 2017 to 2024 - BASE awarded by National Institutes of Health 2017 - 2024
  • A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) awarded by Apellis Pharmaceuticals, Inc 2019 - 2024
  • GS US 339 1559 awarded by Gilead Sciences, Inc. 2017 - 2022
  • Phase II study to evaluate safety of Azacitidine PLUS Durvalumab (medi4736) in MDS/AML awarded by Celgene Corporation 2016 - 2021
  • SGN33A-005 CASCADE awarded by Seattle Genetics, Inc 2016 - 2021
  • AC220-A-U302 QuANTUM-First awarded by Daiichi Sankyo Inc 2016 - 2021
  • Phase III study of AG-221(CC-90007) with late AML harboring Isocitrate Dehydrogenase 2 mutation awarded by Celgene Corporation 2016 - 2021
  • An Open Label study to assess the safety of APL-2 as an Add-on to standard of care in subjects with PNH awarded by Apellis Pharmaceuticals, Inc 2014 - 2019
  • Eqapol Opt 1 -2018-2019 awarded by National Institutes of Health 2017 - 2019
  • RA101495-01.203 awarded by Ra Pharmaceuticals, Inc 2017 - 2018
  • RA101495-01-202 awarded by Ra Pharmaceuticals, Inc 2017 - 2018
  • A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent subjects with IPSS Low or Intermediate-1 awarded by Janssen Research & Development, LLC 2016 - 2018
  • Pevonedistat-2001 awarded by Millennium Pharmaceuticals, Inc. 2016 - 2018
  • ALXN1210-PNH-301 awarded by Alexion Pharmaceuticals, Inc. 2017
  • EQAPOL - 2016 to 2017 - Option 6 - BASE awarded by National Institutes of Health 2010 - 2017
  • EQAPOL Option 5 awarded by National Institutes of Health 2010 - 2017
  • Role Of C-Kit In Early Hematopoiesis awarded by National Institutes of Health 1991 - 1996
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study..” British Journal of Haematology 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.
       Full Text
    • Griffin, Patrick T., Rami S. Komrokji, Carlos M. De Castro, David A. Rizzieri, Magda Melchert, Alan F. List, and Jeffrey E. Lancet. “A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy..” American Journal of Hematology 90, no. 9 (September 2015): 796–99. https://doi.org/10.1002/ajh.24087.
       Full Text
    • Greenberg, P. L., R. M. Stone, R. Bejar, J. M. Bennett, C. D. Bloomfield, U. Borate, C. M. De Castro, et al. “Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines.” Jnccn Journal of the National Comprehensive Cancer Network 13, no. 3 (March 1, 2015): 261–72. https://doi.org/10.6004/jnccn.2015.0038.
       Full Text
    • Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..” Leukemia & Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
       Full Text
    • Greenberg, Peter L., Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H Joachim Deeg, et al. “Myelodysplastic syndromes: clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 7 (July 2013): 838–74. https://doi.org/10.6004/jnccn.2013.0104.
       Full Text
    • Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..” Cancer Investigation 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
       Full Text
    • Hillmen, P., P. Muus, A. Röth, M. O. Elebute, A. M. Risitano, H. Schrezenmeier, J. Szer, et al. “Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.” British Journal of Haematology 162, no. 1 (2013): 62–73. https://doi.org/10.1111/bjh.12347.
       Full Text
    • Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia..” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.
       Full Text  Link to Item
    • Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.
       Full Text
    • Mohanty, Bibhu D., and Carlos M. De Castro. “Too many clots for comfort..” The American Journal of Medicine 125, no. 3 (March 2012): 243–45. https://doi.org/10.1016/j.amjmed.2011.09.002.
       Full Text
    • Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia..” Leukemia & Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.
       Full Text
    • Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target..” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.
       Full Text  Link to Item
    • Greenberg, Peter L., Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, James M. Foran, et al. “NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes..” Journal of the National Comprehensive Cancer Network : Jnccn 9, no. 1 (January 2011): 30–56. https://doi.org/10.6004/jnccn.2011.0005.
       Full Text
    • Advani, Anjali S., Mazyar Shadman, Francis Ali-Osman, Andrew Barker, Lisa Rybicki, Matt Kalaycio, Mikkael A. Sekeres, et al. “A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse..” Clinical Lymphoma, Myeloma & Leukemia 10, no. 6 (December 2010): 473–76. https://doi.org/10.3816/clml.2010.n.082.
       Full Text
    • Dimopoulos, Meletios, Adrian Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, et al. “The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function..” Cancer 116, no. 16 (August 2010): 3807–14. https://doi.org/10.1002/cncr.25139.
       Full Text
    • Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy..” Cancer Investigation 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
       Full Text
    • Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma..” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
       Full Text
    • Friedman, Daphne R., J Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, et al. “A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia..” Clin Cancer Res 15, no. 22 (November 15, 2009): 6947–55. https://doi.org/10.1158/1078-0432.CCR-09-1132.
       Full Text  Link to Item
    • Frytak, Jennifer R., Henry J. Henk, Carlos M. De Castro, Rachel Halpern, and Michael Nelson. “Estimation of economic costs associated with transfusion dependence in adults with MDS..” Current Medical Research and Opinion 25, no. 8 (August 2009): 1941–51. https://doi.org/10.1185/03007990903076699.
       Full Text
    • Rizzieri, David A., Jenny A. O’Brien, Gloria Broadwater, Carlos M. Decastro, Prakash Dev, Louis Diehl, Anne Beaven, et al. “Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia..” Cancer 115, no. 13 (July 2009): 2922–29. https://doi.org/10.1002/cncr.24379.
       Full Text
    • Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70215-2.
       Full Text
    • Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70210-3.
       Full Text
    • Grinblatt, David L., Daohai Yu, Vera Hars, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, et al. “Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)..” Cancer 115, no. 1 (January 2009): 84–93. https://doi.org/10.1002/cncr.23995.
       Full Text
    • Weinberg, J. B., A. D. Volkheimer, M. Mihovilovic, N. Jiang, Y. Chen, K. Bond, J. O. Moore, et al. “Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia..” Leukemia 22, no. 12 (December 2008): 2184–92. https://doi.org/10.1038/leu.2008.241.
       Full Text
    • Greenberg, Peter L., Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, H Joachim Deeg, et al. “Myelodysplastic syndromes..” Journal of the National Comprehensive Cancer Network : Jnccn 6, no. 9 (October 2008): 902–26. https://doi.org/10.6004/jnccn.2008.0072.
       Full Text
    • Rao, Arati V., Islam R. Younis, Gregory J. Sand, Ivan Spasojevic, David J. Adams, Carlos M. Decastro, John P. Gockerman, et al. “Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia..” Leukemia & Lymphoma 49, no. 8 (August 2008): 1523–29. https://doi.org/10.1080/10428190802210700.
       Full Text
    • Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, et al. “Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria..” Blood 111, no. 4 (February 2008): 1840–47. https://doi.org/10.1182/blood-2007-06-094136.
       Full Text
    • Weinberg, J Brice, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, et al. “Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia..” American Journal of Hematology 82, no. 12 (December 2007): 1063–70. https://doi.org/10.1002/ajh.20987.
       Full Text
    • Fock, K. M., A. Wagner, M. A. Ahad, D. S. Ahmed, F. Ahmed, M. M. Ahmed, M. S. Ali, et al. “Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.” Journal of Gastroenterology and Hepatology (Australia) 22, no. 8 (August 1, 2007): 1190–98. https://doi.org/10.1111/j.1440-1746.2007.04955.x.
       Full Text
    • Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Raymond L. Comenzo, Carlos M. De Castro, et al. “Multiple myeloma. Clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 5, no. 2 (February 2007): 118–47. https://doi.org/10.6004/jnccn.2007.0014.
       Full Text
    • Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 6 (February 2007): 690–97. https://doi.org/10.1200/jco.2006.07.0953.
       Full Text
    • Wanko, Sam O., and Carlos de Castro. “Hairy cell leukemia: an elusive but treatable disease..” The Oncologist 11, no. 7 (July 2006): 780–89. https://doi.org/10.1634/theoncologist.11-7-780.
       Full Text
    • Kantarjian, Hagop, Jean-Pierre J. Issa, Craig S. Rosenfeld, John M. Bennett, Maher Albitar, John DiPersio, Virginia Klimek, et al. “Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study..” Cancer 106, no. 8 (April 2006): 1794–1803. https://doi.org/10.1002/cncr.21792.
       Full Text
    • Greenberg, Peter L., Maria R. Baer, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, Marcel P. Devetten, et al. “Myelodysplastic syndromes clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 4, no. 1 (January 2006): 58–77. https://doi.org/10.6004/jnccn.2006.0010.
       Full Text
    • Talbot, Jeffrey, Valerie K. Ibom, David A. Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M. DeCastro, Joseph O. Moore, et al. “Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma..” Clinical Lymphoma 5, no. 2 (September 2004): 116–22. https://doi.org/10.3816/clm.2004.n.018.
       Full Text
    • Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma..” Blood 104, no. 3 (August 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
       Full Text
    • Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma..” Cancer 100, no. 11 (June 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
       Full Text
    • Nishimura, Jun-Ichi, Yuzuru Kanakura, Russell E. Ware, Tsutomu Shichishima, Hideki Nakakuma, Haruhiko Ninomiya, Carlos M. Decastro, et al. “Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan..” Medicine 83, no. 3 (May 2004): 193–207. https://doi.org/10.1097/01.md.0000126763.68170.46.
       Full Text
    • Ibom, Valerie K., Robert G. Prosnitz, Jerald Z. Gong, Joseph O. Moore, Carlos M. DeCastro, Leonard R. Prosnitz, David A. Rizzieri, and Jon P. Gockerman. “Rituximab in lymphocyte predominance Hodgkin's disease: a case series..” Clinical Lymphoma 4, no. 2 (September 2003): 115–18. https://doi.org/10.3816/clm.2003.n.021.
       Full Text
    • Talbot, Jeffrey, David A. Rizzieri, Carlos M. DeCastro, Joseph O. Moore, Patrick Buckley, Rhonda Laney, Diane Stevenson, Heather Brumbaugh, and Jon P. Gockerman. “High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series..” American Journal of Hematology 73, no. 4 (August 2003): 295–96. https://doi.org/10.1002/ajh.10362.
       Full Text
    • Heeney, Matthew M., Susan M. Ormsbee, M Anthony Moody, Thad A. Howard, Carlos M. DeCastro, and Russell E. Ware. “Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria..” Molecular Genetics and Metabolism 78, no. 4 (April 2003): 291–94. https://doi.org/10.1016/s1096-7192(03)00047-7.
       Full Text
    • Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 9, no. 2 (February 2003): 663–68.
    • Castro, Carlos M. de. “Commentary: targeting myelodysplastic syndromes..” Leukemia Research 26, no. 8 (August 2002). https://doi.org/10.1016/s0145-2126(02)00024-3.
       Full Text
    • Bass, Adam J., Jon P. Gockerman, Eve Hammett, Carlos M. DeCastro, David J. Adams, Gary L. Rosner, Nancy Payne, et al. “Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, no. 13 (July 2002): 2995–3000. https://doi.org/10.1200/jco.2002.08.166.
       Full Text
    • Kornblith, Alice B., James E. Herndon, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, James F. Holland, Bayard L. Powell, et al. “Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, no. 10 (May 2002): 2441–52. https://doi.org/10.1200/jco.2002.04.044.
       Full Text
    • McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia..” Leukemia & Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
       Full Text
    • Silverman, Lewis R., Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland, Rosalie Odchimar-Reissig, Richard M. Stone, et al. “Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, no. 10 (May 2002): 2429–40. https://doi.org/10.1200/jco.2002.04.117.
       Full Text
    • Rizzieri, David A., Adam J. Bass, Gary L. Rosner, Jon P. Gockerman, Carlos M. DeCastro, William P. Petros, David J. Adams, et al. “Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, no. 3 (February 2002): 674–79. https://doi.org/10.1200/jco.2002.20.3.674.
       Full Text
    • Ware, R. E., C. V. Pickens, C. M. DeCastro, and T. A. Howard. “Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes..” Experimental Hematology 29, no. 12 (December 2001): 1403–9. https://doi.org/10.1016/s0301-472x(01)00746-9.
       Full Text
    • Rizzieri, D. A., J. P. Gockerman, C. M. Decastro, S. Lilly, and T. Foster. “Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies.” Blood 96, no. 11 PART II (December 1, 2000).
    • Ware, R. E., C. V. Pickens, C. M. Decastro, and T. A. Howard. “Circulating pig-a mutant t lymphocytes in healthy adults and patients with bone marrow failure syndromes including pnh.” Blood 96, no. 11 PART I (December 1, 2000).
    • Castro, C. M. de, S. M. Rabe, S. D. Langdon, D. E. Fleenor, K. Slentz-Kesler, M. N. Ahmed, M. B. Qumsiyeh, and R. E. Kaufman. “Genomic structure and chromosomal localization of the novel ETS factor, PE-2 (ERF)..” Genomics 42, no. 2 (June 1997): 227–35. https://doi.org/10.1006/geno.1997.4730.
       Full Text
    • Mann, K. P., C. M. DeCastro, J. Liu, J. O. Moore, S. H. Bigner, and S. T. Traweek. “Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes..” Am J Clin Pathol 107, no. 6 (June 1997): 653–60. https://doi.org/10.1093/ajcp/107.6.653.
       Full Text  Link to Item
    • He, J., C. M. deCastro, G. R. Vandenbark, J. Busciglio, and D. Gabuzda. “Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene..” Proceedings of the National Academy of Sciences of the United States of America 94, no. 8 (April 1997): 3954–59. https://doi.org/10.1073/pnas.94.8.3954.
       Full Text
    • Wuebbens, M. W., E. D. Roush, C. M. Decastro, and C. A. Fierke. “Cloning, sequencing, and recombinant expression of the porcine inhibitor of carbonic anhydrase: a novel member of the transferrin family..” Biochemistry 36, no. 14 (April 1997): 4327–36. https://doi.org/10.1021/bi9627424.
       Full Text
    • Fleenor, D. E., S. D. Langdon, C. M. deCastro, and R. E. Kaufman. “Comparison of human and Xenopus GATA-2 promoters..” Gene 179, no. 2 (November 1996): 219–23. https://doi.org/10.1016/s0378-1119(96)00355-1.
       Full Text
    • Vandenbark, G. R., Y. Chen, E. Friday, K. Pavlik, B. Anthony, C. deCastro, and R. E. Kaufman. “Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements..” Cell Growth & Differentiation : The Molecular Biology Journal of the American Association for Cancer Research 7, no. 10 (October 1996): 1383–92.
    • deCastro, C. M., S. M. Denning, S. Langdon, G. R. Vandenbark, J. Kurtzberg, R. Scearce, B. F. Haynes, and R. E. Kaufman. “The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes..” Experimental Hematology 22, no. 10 (September 1994): 1025–33.
    • Castro, C. M. de, B. Devlin, D. E. Fleenor, M. E. Lee, and R. E. Kaufman. “A novel beta-globin mutation, beta Durham-NC [beta 114 Leu-->Pro], produces a dominant thalassemia-like phenotype..” Blood 83, no. 4 (February 1994): 1109–16.
    • Bowen, D. T., R. A. Padua, A. K. Burnett, C. M. DeCastro, and R. E. Kaufman. “Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots.” Leukemia 7, no. 11 (January 1, 1993): 1883–85.
    • Vandenbark, G. R., C. M. deCastro, H. Taylor, S. Dew-Knight, and R. E. Kaufman. “Cloning and structural analysis of the human c-kit gene..” Oncogene 7, no. 7 (July 1992): 1259–66.

  • Conference Papers

    • Hillmen, Peter, Petra Muus, Alexander Röth, Modupe O. Elebute, Antonio M. Risitano, Hubert Schrezenmeier, Jeffrey Szer, et al. “Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria..” In British Journal of Haematology, 162:62–73, 2013. https://doi.org/10.1111/bjh.12347.
       Full Text
• Teaching & Mentoring
• 

  Recent Courses

  • MEDICINE 402C: Medical Sub-Internship in Hematology-Oncology 2019
  • MEDICINE 425C: Clinical Coagulation 2019
  • MEDICINE 434C: Outpatient Hematology-Oncology (Duke or Durham VA) 2019
  • MEDICINE 438C: Clinical Hematology and Oncology Consults (Duke or Durham VA) 2019

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.